



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center - WO66-G609  
Silver Spring, MD 20993-0002

Sightline Technologies, Ltd.  
% Jonathan S. Kahan  
Hogan & Hartson L.L.P.  
Columbia Square  
555 Thirteenth Street, N.W.  
Washington, DC 20004-1109

JUL 27 2015

Re: K032688  
Trade/Device Name: ColonSight® Model 510B  
Regulation Number: 21 CFR 876.1500  
Regulation Name: Endoscope and accessories  
Regulatory Class: II  
Product Code: FDF  
Dated (Date on orig SE ltr): November 24, 2003  
Received (Date on orig SE ltr): December 8, 2003

Dear Mr. Kahan,

This letter corrects our substantially equivalent letter of March 5, 2004.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be

found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

**Benjamin R. Fisher -S**

Benjamin R. Fisher, Ph.D.  
Director  
Division of Reproductive, Gastro-Renal,  
and Urological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

**Indications for Use Statement**

Page 1 of 1

510(k) Number (if known): K032688

Device Name: ColonoSight Model 510B

**Indications for use:** The ColonoSight provides visualization and therapeutic access to the lower gastrointestinal tract. Visualization is provided via a video monitor. The lower gastrointestinal tract includes, but is not restricted to, the organs, tissues, and subsystems of the large bowel. The device is introduced rectally as with any standard colonoscope, when indications consistent with the requirement for the procedure are observed in adult patient populations.

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use  \_\_\_\_\_  
Use \_\_\_\_\_  
(Per 21 C.F.R. 801.109)  
2-96)

Or Over-The-Counter  
(Optional Format 1-

Nancy C. Brogdon  
(Division Sign-Off)  
Division of Reproductive, Abdominal,  
and Radiological Devices  
510(k) Number K032688

MAR - 5 2004

K 032688

pg 1 of 2

**510(k) SUMMARY**

**Sightline Technologies' ColonoSight Model 510B**

**Submitter's Name, Address, Telephone Number, Contact Person  
and Date Prepared**

Sightline Technologies Ltd.  
Advanced Technology Center  
31905 Haifa  
ISRAEL

Phone: +972-4-855-0447  
Facsimile: +972-4-855-0164

Contact Person: Sharon Goldfarb-Albak

Date Prepared:

**Name of Device and Name/Address of Sponsor**

ColonoSight Model 510B

Sightline Technologies Ltd.  
Advanced Technology Center  
31905 Haifa  
ISRAEL

Phone: +972-4-855-0447  
Facsimile: +972-4-855-0164

**Common or Usual Name**

Colonoscope and Accessories

**Classification Name**

Colonoscope and Accessories

**Predicate Devices**

Pentax Video Colonoscopes (K961570, K961563, and K951579).  
EndoSheath® (K990354, K012543, and K021344),  
with VSI C-F100 Colonoscope (K943895),  
Sightline RectoSight (K994130, K011782).

**Intended Use**

The ColonoSight Model 510B is intended to provide visualization (via a video monitor) and therapeutic access to the lower gastrointestinal tract. The lower gastrointestinal tract includes, but is not restricted to, the organs, tissues, and subsystems of the large bowel. The device is introduced rectally as with any standard colonoscope, when indications consistent with the requirement for the procedure are observed in adult patient populations.

**Technological Characteristics and Substantial Equivalence**

The ColonoSight is a colonoscope covered with a disposable protective sheath and incorporating disposable channels for insufflation, irrigation and suction/therapeutic interventions. Intubation is performed using an "air assisted push technology". The main components are: EndoSight, Camera Control Unit, Hydro-pneumatic Control Unit; disposable ColonoSleeve and disposable Hub.

The ColonoSight is substantially equivalent to the other currently marketed Colonoscopes which are referenced above. The ColonoSight and its predicate devices are Colonoscopes. Thus, the ColonoSight raises no new issues of safety or effectiveness.

**Performance Data**

Microbiological barrier bench tests were performed on the ColonoSleeve component both in a laboratory and in animals. The ColonoSight system was tested for functionality. Optical Performance tests were performed both with and without the disposable components. Biocompatibility and pyrogenicity tests were performed. In addition, clinical trials were performed with no recorded complications. In all instances, the ColonoSight functioned as intended and performed as expected.